CAR T-Cell Therapy: FDA Approves ‘Living Drugs’ for Cancer Treatment in Children and Adults
Learning Objectives and CME/Disclosure Information
This activity is intended for healthcare providers delivering care to women and their families.
After completing this activity, the participant should be better able to:
1. Explain the fundamental technology underlying CAR T-cell construction 2. Discuss how CAR T-cell therapy is being used in oncology
Estimated time to complete activity: 0.25 hours
Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.
Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.
Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.
Method of Participation and Request for Credit
Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from 12/31/2017 through 1/25/2023, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.
For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.
‘CAR’ (chimeric antigen receptor) refers to the synthetic receptors that are genetically engineered and integrated into the T-cell surface
CAR T-cell therapy is a type of adoptive cell transfer (ACT) where a patient’s cells are removed, genetically engineered to attack her cancer cells and then returned back to the patient
HOW ARE CAR T-CELLS MADE AND USED TO ATTACK CANCER CELLS?
The genetically engineered CAR is not an antibody found in nature but rather is a synthetic construct that is made up of various fragments and domains
T-cells from a patient with cancer are engineered to produce these CAR T-cells, outfitted with synthetic antibodies specific to the target cancer cell antigen, which are then infused back into the patient
Scientists choose domains that will maximize recognition of the target antigen on the tumor cell
Domains within the cell are also important and designed to affect cell function
Continuing research has led to improvements in
Expansion (ability of CAR T-cells to multiply after infusion into the patient)
Persistence (survival after infusion into the patient)
Production time (from weeks to days)
FDA APPROVAL 2017:
FDA (August 2017) approved the first CAR T-cell therapy, tisagenlecleucel, for children with acute lymphoblastic leukemia (ALL) who have relapsed at least twice or who have not responded to standard therapy
The synthetic antibodies target the CD19 antigen found only on B-cells
The CAR T-cells undergo expansion in the laboratory, are infused back into the patient following lymphodepletion and then will undergo expansion again
Many of the children in the tisagenlecleucel trials have had complete long lasting remissions
Previously, no known treatment available
The FDA granted tisagenlecleucel Priority Review and Breakthrough Therapy designations
FDA (October 2017) approved the first drug for adults, axicabtagene ciloleucel, for the treatment of an aggressive type of non-Hodgkin lymphoma
This CAR T-cell therapy targets CD19 cells and is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma
Individuals with DLBCL will go into remission after treatment but approximately a third either don’t respond or relapse and on average will survive only 6 months
In a drug trial that included 101 patients, 36% went in to remission and in 82%, the tumor shrank by ≥ 50%
Known risks were seen in the trial, including brain toxicity
Examples of ACT: TCR T-cells and CAR T-cells (tap to enlarge)
Credit: National Cancer Institute
Other examples of ACT beyond CAR T
Tumor-Infiltrating Lymphocytes (TILs): Immune cells that can penetrate tissues around the tumor based on cancer mutation recognition
Currently being studied in colorectal and liver cancer
T-cell Receptors (TCRs): As opposed to CAR T approach, TCRs use naturally receptors that recognize antigens within tumor cells
Currently being studied in melanoma and sarcoma
CAR T-cell therapy side effects include
Cytokine-release syndrome (CRS) that results from rapid and massive release of cytokines into the bloodstream resulting in fevers and hypotension
Indicates T-cells are working
CRS manageable with supportive therapies
B-cell aplasia, where B-cells, including normal cells, are killed off by the CAR T-cell therapy
Treatment includes immunoglobin therapy to fight dangerous infection
Cerebral edema noted in some trials but not others
Neurotoxicity (confusion or seizure-like activity) which is short lived and reversible
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan